Axonal Damage But No Increased Glial Cell Activity in the Normal-Appearing White Matter of Patients with Clinically Isolated Syndromes Suggestive of Multiple Sclerosis Using High-Field Magnetic Resonance Spectroscopy

References

1. ↵
   Ge Y. Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 2006;27:1165–76

   Abstract/FREE Full Text
2. ↵
   Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059–69

   Abstract/FREE Full Text
3. Tintoré M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702–06

   Abstract/FREE Full Text
4. Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003;53:718–24

   CrossRefPubMedWeb of Science
5. ↵
   Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004;61:217–21

   CrossRefPubMedWeb of Science
6. ↵
   Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006;27:455–61

   FREE Full Text
7. ↵
   Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20:1619–27

   Abstract/FREE Full Text
8. ↵
   Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003;250:1407–19

   CrossRefPubMedWeb of Science
9. ↵
   Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006;66:1384–89

   Abstract/FREE Full Text
10. ↵
    Geurts JJ, Reuling IEW, Vrenken H, et al. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 2006;55:478–83

    CrossRefPubMedWeb of Science
11. ↵
    He J, Inglese M, Li BS, et al. Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience. Radiology 2005;234:211–17

    PubMedWeb of Science
12. ↵
    Simmons ML, Frondonza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37–45

    CrossRefPubMedWeb of Science
13. Nakano M, Ueda H, Li J, et al. Measurement of regional N-acetylaspartate after transient global ischemia in gerbils with and without ischemic tolerance: an index of neuronal survival. Ann Neurol 1998;44:334–40

    CrossRefPubMedWeb of Science
14. ↵
    Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289–98

    CrossRefPubMedWeb of Science
15. ↵
    Leary SM, Davie CA, Parker GJ, et al. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 1999;246:1023–26

    CrossRefPubMedWeb of Science
16. ↵
    van Walderveen MA, Barkhof F, Pouwels PJ, et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46:79–87

    CrossRefPubMedWeb of Science
17. ↵
    De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469–77

    Abstract/FREE Full Text
18. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65–70

    CrossRefPubMedWeb of Science
19. ↵
    Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62:569–73

    CrossRefPubMedWeb of Science
20. ↵
    Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing remitting multiple sclerosis. Brain 2002;125:2342–52

    Abstract/FREE Full Text
21. ↵
    Kapeller P, Brex PA, Chard D, et al. Quantitative 1H MRS imaging 14 years after presenting with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2002;8:207–10

    Abstract/FREE Full Text
22. ↵
    Kapeller P, McLean MA, Griffin CM, et al. Preliminary evidence for neuronal damage in cortical grey and normal apprearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 2001;248:131–38

    CrossRefPubMedWeb of Science
23. ↵
    Vrenken H, Barkhof F, Uitdehaag BM, et al. MR spectroscopic evidence of glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 2005;53:256–66

    CrossRefPubMedWeb of Science
24. ↵
    Brex PA, Gomez-Anson B, Parker GJ, et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 1999;166:16–22

    CrossRefPubMedWeb of Science
25. ↵
    Fernando KTM, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinical isolated syndromes suggestive of multiple sclerosis. Brain 2004;127:1361–69

    Abstract/FREE Full Text
26. ↵
    Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur Radiol 2005;15:946–59

    CrossRefPubMedWeb of Science
27. ↵
    Keiper MD, Grossmann RI, Hirsch JA, et al. MR identification of white matter abnormalities in multiple sclerosis: a comparison between 1.5T and 4T. AJNR Am J Neuroradiol 1998;19:1489–93

    Abstract
28. ↵
    Wattjes MP, Lutterbey GG, Harzheim M, et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5T with 3.0T. Eur Radiol 2006;16:2067–73

    CrossRefPubMedWeb of Science
29. Wattjes MP, Harzheim M, Kuhl CK, et al. Does high-field MRI have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic magnetic resonance imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 2006;27:1794–98

    Abstract/FREE Full Text
30. ↵
    Gonen O, Gruber S, Mi BS, et al. Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal-to-noise ratio and resolution comparison. AJNR Am J Neuroradiol 2001;22:1727–31

    Abstract/FREE Full Text
31. ↵
    Jansen JF, Backes WH, Nicolay K, et al. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006;240:318–32

    CrossRefPubMedWeb of Science
32. ↵
    Srinivasan R, Vigneron D, Sailasuta N, et al. A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain. Magn Reson Imaging 2004;22:523–28

    CrossRefPubMedWeb of Science
33. ↵
    Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–46

    CrossRefPubMedWeb of Science
34. ↵
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52

    Abstract/FREE Full Text
35. ↵
    Leary SM, Brex PA, MacManus DG, et al. A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. Magn Reson Imag 2000;18:455–59

    CrossRefPubMedWeb of Science
36. ↵
    Wattjes MP, Lutterbey GG, Harzheim M, et al. Imaging of inflammatory lesions at 3.0 Tesla in patients with clinically isolated syndromes suggestive of multiple sclerosis: a comparison of fluid-attenuated inversion recovery with T2 turbo spin-echo. Eur Radiol 2006;16:1494–500

    CrossRefPubMed
37. ↵
    Wiedermann D, Schuff N, Matson GB, et al. Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: metabolite distributions and reliability. Magn Reson Imaging 2001;19:1073–80

    CrossRefPubMedWeb of Science
38. ↵
    Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12:141–52

    CrossRefPubMed
39. ↵
    Vanhamme L, van den Boogaart A, van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35–43

    CrossRefPubMedWeb of Science
40. ↵
    Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433–37

    Abstract/FREE Full Text
41. ↵
    Tourbah A, Stievenart JL, Abanou A, et al. Normal-appearing white matter in optic neuritis and multiple sclerosis: a comparative proton spectroscopy study. Neuroradiology 1999;41:738–43

    CrossRefPubMedWeb of Science
42. ↵
    Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain 2005;128:1016–25

    Abstract/FREE Full Text
43. ↵
    Kapeller P, Ropele S, Enzinger C, et al. Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy. J Neurol 2005;252:1229–34

    CrossRefPubMedWeb of Science
44. ↵
    Tiberio M, Chard DT, Altmann DR, et al. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol 2006;253:224–30

    CrossRefPubMedWeb of Science